BRAF wild-type melanoma in situ arising in a BRAF V600E mutant dysplastic nevus.

IMPORTANCE The BRAF V600E mutation accounts for the majority of BRAF mutations found in cutaneous melanoma and is also commonly found in nevi. We used dermoscopy-targeted sampling and a microbiopsy device coupled with DNA sequence analysis to highlight BRAF V600E heterogeneity within a multicomponent melanocytic proliferation. This sampling technique demonstrates the prospect of in vivo application in a clinical setting. OBSERVATIONS A man in his 50s with Fitzpatrick skin type II presented with an irregularly pigmented melanocytic lesion on his back that met melanoma-specific dermoscopic criteria, and diagnostic shave excision of the lesion was performed. Histopathologic analysis revealed a melanoma in situ arising in a dysplastic nevus. Dermoscopy-targeted microbiopsy specimens were taken across the lesion, and genotyping was carried out on extracted DNA samples for BRAF and NRAS mutations. The melanoma in situ showed only BRAF wild-type results, while the dysplastic nevus showed both BRAF wild-type and BRAF V600E mutations. Sequencing in all DNA samples revealed NRAS wild-type genotype. CONCLUSIONS AND RELEVANCE Dermoscopy-targeted sampling and genotyping of a melanoma in situ arising in a dysplastic nevus revealed a phenotype-genotype paradox that confounds the exclusive significance of BRAF and NRAS mutations in melanoma pathogenesis. Further studies are required to investigate the importance of other candidate genes linked to melanomagenesis.

[1]  R. Sturm,et al.  BRAFV600E mutation status of involuting and stable nevi in dabrafenib therapy with or without trametinib. , 2014, JAMA dermatology.

[2]  M. Bosenberg,et al.  Melanoma metastasis: new concepts and evolving paradigms , 2014, Oncogene.

[3]  H. Soyer,et al.  Effects of ex vivo skin microbiopsy on histopathologic diagnosis in melanocytic skin lesions. , 2013, JAMA dermatology.

[4]  H. Soyer,et al.  The opportunity for microbiopsies for skin cancer. , 2013, Future oncology.

[5]  P. Tschandl,et al.  NRAS and BRAF Mutations in Melanoma-Associated Nevi and Uninvolved Nevi , 2013, PloS one.

[6]  H. Soyer,et al.  Microbiopsy engineered for minimally invasive and suture-free sub-millimetre skin sampling , 2013, F1000Research.

[7]  Jane Fridlyand,et al.  Improving Melanoma Classification by Integrating Genetic and Morphologic Features , 2008, PLoS medicine.

[8]  R. Alani,et al.  BRAF kinase in melanoma development and progression , 2008, Expert Reviews in Molecular Medicine.

[9]  N. Thomas BRAF somatic mutations in malignant melanoma and melanocytic naevi , 2006, Melanoma research.

[10]  D. Bennett Human melanocyte senescence and melanoma susceptibility genes , 2003, Oncogene.

[11]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[12]  D. Duffy,et al.  Phenotypic characterization of nevus and tumor patterns in MITF E318K mutation carrier melanoma patients. , 2014, The Journal of investigative dermatology.

[13]  P. Meltzer,et al.  High frequency of BRAF mutations in nevi , 2003, Nature Genetics.

[14]  I. Barkan Industry invites regulation: the passage of the Pure Food and Drug Act of 1906. , 1985, American journal of public health.

[15]  Junfeng Xia,et al.  Cancer Biology and Signal Transduction a Meta-analysis of Somatic Mutations from next Generation Sequencing of 241 Melanomas: a Road Map for the Study of Genes with Potential Clinical Relevance , 2022 .